In fact, between increasing generic competition to Copaxone andpricing pressure on the rest of its products, Teva's sales fell by an alarming 16% in 2018.
梯瓦和乌克兰官员之间的咨询协议每年都以相同的条款续签,直到2011年底或前后。
The consulting agreement between Teva and Ukrainian Official was renewed annually, on the same terms, until in or around late 2011.
他表示,梯瓦将不再对预期的仿制药价格发展发表评论,并指出这种估计导致下滑幅度增大。
He said Teva would no longer comment on expected generic price developments, noting such estimates were leading to steeper declines.
梯瓦在一份声明中表示,“这起新诉讼中的指控,以及诉讼中更为普遍的指控只是指控而已。
Teva added in a statement:“The allegations in this new complaint, and in the litigation more generally are just that- allegations.”.
他指出梯瓦几个月来一直在积极与医疗保险公司和其他客户谈判如何以最佳方式让患者获取新药。
Teva has been actively negotiating with health insurers and other payers for months on how best to allow patients access to the drug.
梯瓦于1996年推出的Copaxone为其首个主要品牌药品,现在仍是治疗多发性硬化症的主要药物。
Launched in 1996 by Teva as its first major brand-name drug, Copaxone is still the leading medication for multiple sclerosis patients.
不过,梯瓦还需要解决阿片类药物诉讼,这是该行业面临的最重大的法律威胁之一。
The pharma also needs to resolve the opioid litigation, one of the most significant legal threats facing the industry.
梯瓦将继续探fremanezumab的其他用途,包括治疗创伤后头痛(目前正在进行一项II期研究)。
Teva continues to explore other uses for fremanezumab, including the treatment of post-traumatic headache(currently being studied in a Phase II trial).
中文
Bahasa indonesia
日本語
عربى
Български
বাংলা
Český
Dansk
Deutsch
Ελληνικά
Español
Suomi
Français
עִברִית
हिंदी
Hrvatski
Magyar
Italiano
Қазақ
한국어
മലയാളം
मराठी
Bahasa malay
Nederlands
Norsk
Polski
Português
Română
Русский
Slovenský
Slovenski
Српски
Svenska
தமிழ்
తెలుగు
ไทย
Tagalog
Turkce
Українська
اردو
Tiếng việt